AdvisorShares Dorsey Wright Short ETF

Somnigroup International Proposes All-Stock Acquisition of Leggett & Platt

Rockefeller Capital Management Significantly Increased Holdings in Concho Resources

Wells Fargo Analyst Maintains Buy Rating for Sarepta Therapeutics

Sarepta Therapeutics Receives FDA Approval to Administer ELEVIDYS Gene Therapy

Sarepta Therapeutics Updates Clinical Trial Progress for SRP-1003 for Type 1 Myotonic Dystrophy

Revvity Raises EPS Forecast and Announces Stock Repurchase Plan

Sarepta Updates Elevidys Prescribing Information to Address Liver Risks

U.S. Bank Securities and Citibank Maintain Sell Rating on Sarepta Therapeutics

FDA Approves Sarepta Therapeutics Gene Therapy Elevidys New Label

Quinn Opportunity Partners LLC Acquired Sarepta Therapeutics Shares in Q2

Revvity Inc. Receives Analyst Ratings, Shares Rise, and Announces Stock Repurchase

Brook Company Director John A. Ornell Sells Common Stock

Revvity, Inc. Releases Advanced Somatic Cancer Reference Standards

Revvity, Inc. Acquires ACD/Labs to Enhance Signals Platform

JPMorgan Downgrades Goodyear Tire & Rubber's Target Price to $13

Mizuho Raises Sarepta Therapeutics' Stock Rating

Ear Recommends Healthcare Stocks

Teradata released FY2025 9 Months Earnings on November 4 After-Market EST, with actual revenue of USD 1.242 B and EPS of USD 0.96

Teradata released FY2025 Q3 earnings on November 4 After-Market EST, actual revenue USD 416 M (forecast USD 406.3 M), actual EPS USD 0.42 (forecast USD 0.2464)

Ritu Baral gives Sarepta Therapeutics a hold rating

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Hoyne Bancorp

Tradr 2X Long ASTS Daily ETF

Centene has cut its earnings guidance due to higher-than-expected medical utilization in federal exchange plans and Medicaid reimbursement pressures. This guidance cut raises concerns about profitability, with potential changes in federal exchange subsidy policy affecting Centene's enrollee base. The company's 2025 outlook forecasts a GAAP diluted loss per share not exceeding $12.85, highlighting financial challenges. Investors are urged to consider various perspectives on Centene's fair value, which ranges widely, reflecting uncertainty in its profit profile.

Simplywall

Centene

Guidance Cut From Higher Exchange Costs Could Be A Game Changer For Centene (CNC)

Is Centene Stock Underperforming the S&P 500?

Barchart Option

Is Centene Stock Underperforming the S&P 500?

SRPT

Rothfuss Cristin, VP of Sarepta Therapeutics Inc, filed a Form 4 with the SEC on Dec 2, 2025, disclosing the surrender of 229 shares at $21.12 each, valued at $4,836, to cover option exercise costs or tax liabilities. Ending holdings are 139,756 shares directly. The Washington Service offers insider trading analysis and data services.

Reuters

Sarepta Therap

VP Rothfuss Surrenders 229 Of Sarepta Therapeutics Inc [SRPT]

BRKR

Richard A. Packer, Director of Bruker Corporation, reported the disposal of common shares. The full filing is available via EDGAR, the U.S. SEC's system.

Bruker

Bruker Director Richard A. Packer Reports Disposal of Common Shares

Kurt A. Niemietz, Vice President IR & Treasurer of Kirby Corporation, reported the disposal of common shares of Kirby Corporation. The original filing is available via EDGAR, the U.S. SEC's system, with Ref. ID: 0001193125-25-304746, dated December 02, 2025.

Kirby

Kurt A. Niemietz, VP IR & Treasurer, Reports Disposal of Kirby Corporation Common Shares

Meridian Health Plan of Illinois, part of Centene Corporation, commits $1.15 million over three years to expand the St. Louis Area Foodbank's mobile pantry program, "Food On The Move." This initiative aims to combat food insecurity by delivering healthy food to underserved communities in Illinois, aligning with Meridian's Eat Well, Be Well initiative. The program is expected to serve 60,000 community members by 2028, providing dignity and stability to those in need.

StockTitan

Meridian Health Plan of Illinois Commits $1.15 Million to Expand St. Louis Area Foodbank Mobile Pantry Program | CNC Stock News

Treasurer Niemietz Kurt A of Kirby Corp filed a Form 144 with the SEC to sell 1,500 shares on December 1, 2025. The sale will be conducted through Merrill Lynch & Co Inc. Form 144 is required for selling restricted stock, allowing sales within 90 days of filing.

Treas Niemietz Files To Sell 1,500 Of Kirby Corp [KEX]

Grandeur Peak Global Advisors LLC increased its stake in Bruker Corporation by 3.6% in Q2, making it their 7th largest position. Bruker's stock performance shows a market cap of $7.26 billion and a P/E ratio of 91.83. The company reported Q3 earnings of $0.45 per share, beating estimates. Bruker announced a quarterly dividend of $0.05 per share. Insider trading included sales by Directors John A. Ornell and Cynthia M. Friend. Analysts have recently updated their ratings on BRKR.

Market Beat

Bruker Corporation $BRKR is Grandeur Peak Global Advisors LLC's 7th Largest Position

MRNA

SNYNF

The healthcare sector saw notable stock gains, with Moderna and Centene leading. President Trump opposed extending ACA subsidies, preferring individual payments. The Trump administration secured a 71% discount on Ozempic and Wegovy for Medicare. Sanofi's Paris HQ was raided over a tax fraud probe. The US and UK are nearing a drug pricing deal to boost UK prices in exchange for avoiding tariffs.

Novo Nordisk AS

Moderna

Sanofi

Eli Lilly

Notable healthcare headlines for the week: Sanofi, Eli Lilly, and Novo Nordisk in focus

RVTY

Revvity (RVTY) has seen a 9.5% increase in its stock price since its last earnings report, outperforming the S&P 500's 5% gain. The article discusses analyst expectations for its upcoming earnings, highlighting key metrics like EPS and revenue, and considers fundamental and technical factors that could influence its future performance as it approaches its next report on May 7, 2024.

Revvity

Revvity (RVTY) Up 9.5% Since Last Earnings Report: Can It Continue?

Rockefeller Capital Management L.P. increased its holdings in Centene Corporation by 71% in Q2, owning 22,903 shares valued at $1,243,000. Other institutional investors also adjusted their positions in Centene. The company's stock opened at $39.72, with a market cap of $19.52 billion. Analysts have mixed ratings on Centene, with a consensus price target of $40.00.

Rockefeller Capital Management L.P. Grows Position in Centene Corporation $CNC

KBC Group NV decreased its stake in Sarepta Therapeutics, Inc. by 98.5% in the 2nd quarter, as per its latest SEC filing. The firm now owns 3,152 shares worth $54,000. Other investors have also modified their holdings. Analysts have mixed ratings on SRPT, with a consensus target price of $33.75. Sarepta's recent earnings missed estimates, reporting a revenue of $399.36 million, down 14.5% year-over-year. Sarepta focuses on RNA-targeted therapeutics and gene therapies for rare diseases.

KBC Group NV Cuts Stake in Sarepta Therapeutics, Inc. $SRPT

Health Net, a Centene Corporation company, announced over $1.4 million in investments to combat food insecurity in California. These efforts include grants to food banks and community organizations, aiming to provide immediate relief and long-term solutions. The initiative addresses disruptions in federal nutrition programs and supports local communities. Health Net employees also volunteered over 500 hours to tackle food insecurity. The company collaborates with the California Food is Medicine Coalition to deliver tailored meals and nutrition counseling to those in need.

Recent SNAP Disruptions Highlight Urgent Need for Sustained Action Against Food Insecurity | CNC Stock News

Wells Fargo analyst Yanan Zhu maintained a Buy rating on Sarepta Therapeutics with a $45 price target. Zhu, who covers the Healthcare sector, has an average return of 9.6% and a 37.17% success rate. Mizuho Securities also issued a Buy rating, while Bernstein maintained a Hold rating on Sarepta Therapeutics.

Tip Ranks

Sarepta Therapeutics (SRPT) Gets a Buy from Wells Fargo

Franklin Resources Inc. increased its stake in Kirby Corporation by 42.7% in Q2, owning 632,308 shares worth $71.71 million. Analysts have upgraded Kirby's stock ratings, with price targets ranging from $109 to $128. Kirby's Q3 earnings exceeded expectations, reporting $1.65 EPS and $871.16 million revenue. Institutional investors own 96.15% of Kirby's stock, and insiders have recently sold shares. The stock opened at $107.95, with a market cap of $5.85 billion.

Franklin Resources

Franklin Resources Inc. Boosts Stock Holdings in Kirby Corporation $KEX